Scarica l'app Stockscreener
291.51
1.42%
-4.19
Dopo l'orario di chiusura:
291.51
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$295.70
Aprire:
$296.1
Volume 24 ore:
697.95K
Relative Volume:
1.07
Capitalizzazione di mercato:
$20.51B
Reddito:
$2.36B
Utile/perdita netta:
$236.10M
Rapporto P/E:
88.71
EPS:
3.286
Flusso di cassa netto:
$382.50M
1 W Prestazione:
-1.58%
1M Prestazione:
-12.38%
6M Prestazione:
-4.31%
1 anno Prestazione:
+8.23%
Intervallo 1D:
$291.18
$297.20
Intervallo di 1 settimana:
$290.98
$306.04
Portata 52W:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Nome
Insulet Corporation
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Confronta PODD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
291.51 | 20.80B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
128.47 | 218.16B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.19 | 137.24B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.31 | 135.41B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.57 | 128.03B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.38 | 48.21B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-19 | Aggiornamento | UBS | Neutral → Buy |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Ripresa | Oppenheimer | Outperform |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corporation Borsa (PODD) Ultime notizie
Assessing Insulet (PODD) Valuation After Recent Share Price Pullback - Yahoo Finance
Insulet Corporation Expands Omnipod®? U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating A More Sustainable Future - marketscreener.com
Insulet expands pod recycling program to all U.S. customers By Investing.com - Investing.com India
4 Medical Device Stocks to Buy for Healthy Returns in 2026 - Yahoo Finance Australia
Insulet expands Pod recycling program nationwide across US - StreetInsider
Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future - Yahoo Finance
Munro Partners Purchases Shares of 14,355 Insulet Corporation $PODD - MarketBeat
Castleark Management LLC Takes Position in Insulet Corporation $PODD - MarketBeat
Engineers Gate Manager LP Acquires 96,272 Shares of Insulet Corporation $PODD - MarketBeat
Bellevue Group AG Cuts Holdings in Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Purchased by Occudo Quantitative Strategies LP - MarketBeat
Bayesian Capital Management LP Invests $3.90 Million in Insulet Corporation $PODD - MarketBeat
A Look Into Insulet Inc's Price Over Earnings - Benzinga
WINTON GROUP Ltd Has $1.27 Million Holdings in Insulet Corporation $PODD - MarketBeat
418,356 Shares in Insulet Corporation $PODD Purchased by Qube Research & Technologies Ltd - MarketBeat
Ossiam Sells 6,988 Shares of Insulet Corporation $PODD - MarketBeat
(PODD) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Insulet Corporation $PODD Shares Bought by California Public Employees Retirement System - MarketBeat
Here is Why Growth Investors Should Buy Insulet (PODD) Now - sharewise.com
Natixis Acquires Shares of 27,563 Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Bought by First Trust Advisors LP - MarketBeat
Insider Buying: Timothy Stonesifer Acquires Shares of Insulet Co - GuruFocus
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Insulet Corp Director Timothy C. Stonesifer Buys 962 Shares - TradingView
Insulet Insider Bought Shares Worth $299,884, According to a Recent SEC Filing - marketscreener.com
Insulet : Appoints Cristal Downing to Newly Created Role of Chief Corporate Affairs Officer - marketscreener.com
PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements - Yahoo Finance
Insulet Corporation $PODD Shares Sold by Brown Advisory Inc. - MarketBeat
Patient Monitoring Stocks Q3 In Review: Insulet (NASDAQ:PODD) Vs Peers - Finviz
Insulet (NASDAQ:PODD) Shareholders YoY Returns Are Lagging the Company's 8.5% Five-year Earnings Growth - 富途牛牛
Federated Hermes Inc. Grows Position in Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Purchased by Jump Financial LLC - MarketBeat
FDA clears Insulet’s Omnipod 5 algorithm enhancements - MSN
Insulet gets FDA clearance for updates to Omnipod 5 automated insulin delivery - MSN
Insulet Corporation: Inside the Strategy Driving Its Robust Type 2 Adoption! - Smartkarma
Assessing Insulet’s Valuation After Omnipod Expansion and Recent Share Price Volatility - Yahoo Finance
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
FDA Clearance Of Lower-Target Omnipod 5 Upgrade Could Be A Game Changer For Insulet (PODD) - simplywall.st
Insulet Announces FDA 510(k) Clearance of Omnipod 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience - marketscreener.com
Marshall Wace LLP Boosts Position in Insulet Corporation $PODD - MarketBeat
Baird Financial Group Inc. Reduces Stock Holdings in Insulet Corporation $PODD - MarketBeat
FDA clears Insulet’s enhanced Omnipod 5 insulin delivery system By Investing.com - Investing.com South Africa
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Here's Why Insulet (PODD) is a Strong Growth Stock - sharewise.com
Insulet stock price target maintained at $379 by TD Cowen on FDA clearance - Investing.com Nigeria
FDA Clears Omnipod 5 Algorithm Updates, Adding 100 mg/dL Target Glucose Option - Patient Care Online
FDA OKs Algorithm Updates to Insulet’s Omnipod 5 Insulin Pump - Medical Product Outsourcing
Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience - BioSpace
Insulet announces FDA 510(k) clearance of Omnipod 5 algorithm enhancements - marketscreener.com
TD Cowen Reiterates Buy Rating on Insulet Corporation (PODD) - StreetInsider
Insulet Announces FDA 510(K) Clearance Of Omnipod 5 Algorithm Enhancements - TradingView
Insulet Corporation Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):